Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05000190 · ClinicalTrials.gov registry record · NA

Acute and Chronic Effect of 250 mg Citicoline Consumption on Attention in Adults: A Randomized Trial

A NA study, sponsored by PepsiCo Global R&D.

Completed
Registry status
NA
Development phase
104
Enrollment target

NCT05000190: Completed NA study, sponsored by PepsiCo Global R&D.

NCT05000190 is a NA study that has completed, run by PepsiCo Global R&D. The registered enrollment target is 104 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05000190, a NA study, has completed, sponsored by PepsiCo Global R&D.

COMPLETED
Registry status
NA
Development phase
104 participants
Enrollment target

Study Summary

The primary study objectives are to test whether among a sample of healthy adults consuming: (1) a single capsule containing 250 mg citicoline has an effect on attentional performance 1, 2 and 3 h post-dose compared to placebo (acute effect), and (2) capsule containing 250 mg citicoline per day for 28 consecutive days has an effect on attentional performance compared to placebo (chronic effect).

Primary Outcome

Attention performance during the Connors Continuous Performance Test- version III (CPT-III)

Interventions

  • OTHER Placebo capsule
  • DIETARY_SUPPLEMENT Active capsule

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2021-09-13
Est. Completion 2022-07-19
Phase NA
PepsiCo Global R&D

47 total trials

What the finished NCT05000190 record still lists

NCT05000190 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo capsule is the first listed.

NCT05000190 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05000190 about?

NCT05000190 is a clinical study titled "Acute and Chronic Effect of 250 mg Citicoline Consumption on Attention in Adults: A Randomized Trial". The primary study objectives are to test whether among a sample of healthy adults consuming: (1) a single capsule containing 250 mg citicoline has an effect on attentional performance 1, 2 and 3 h post-dose compared to placebo (acute effect), and (2) capsule containing 250 mg citicoline per day for ...

What is the current status of trial NCT05000190?

This trial is currently completed. It is a NA study. The enrollment target is 104 participants. The study started on 2021-09-13. Estimated completion is 2022-07-19.

What interventions are being tested in trial NCT05000190?

The interventions under investigation include: Placebo capsule (OTHER), Active capsule (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05000190?

This trial is sponsored by PepsiCo Global R&D, which has 47 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05000190's enrollment target sits among peer trials

104 836th of 2000 higher than 1,164 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05000190, the US trial registry maintained by the National Library of Medicine. NCT05000190 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.